polymyalgia rheumatica; fatigue; malaise; generalized joint pain; myalgia; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority-web. regulatory number: nl-lrb-00724347 (ra). other case identifier(s): nl-lrb-00791130 (ra). a 66 year-old male patient received bnt162b2 (comirnaty), administration date 07jun2021 (lot number: fd0785) as dose 2, 0.3 ml single for covid-19 immunisation. the patient's relevant medical history was not reported. concomitant medication(s) included: acetylsalicylzuur (tablet, 30 mg (milligram), disper); crestor (tablet, 10 mg (milligram), filmomhuld). vaccination history included: comirnaty (dose 1, single, strength 0.3 ml, batch/lot number: unknown), administration date: 03may2021, for covid-19 immunisation. the following information was reported: polymyalgia rheumatica (medically significant) with onset 28jul2021, outcome "recovering", described as "polymyalgia rheumatica"; fatigue (non-serious) with onset 28jul2021, outcome "recovering", described as "fatigue"; malaise (non-serious) with onset 28jul2021, outcome "recovering", described as "malaise"; arthralgia (non-serious) with onset 28jul2021, outcome "recovering", described as "generalized joint pain"; myalgia (non-serious) with onset 28jul2021, outcome "recovering", described as "myalgia". no follow-up attempts are possible. no further information is expected. follow-up 1 (14feb2022): this is a spontaneous follow-up report from the same contactable consumer: updated information: the llt for the event 'muscular rheumatism' updated to 'polymyalgia rheumatica'. new reference number added, historical vaccine notes and ongoing was updated as no, biological product, suspect dose number, dose and unit (0.3 ml), dose description for concomitant medications and updated narrative accordingly. no follow-up attempts are possible. no further information is expected